In a conference call to discuss Q3 earnings, CEO Francis deSouza discussed NIPT, oncology, population sequencing, and consumer genomics as potential growth drivers.
During the first year of the TRIDENT-2 study, 74,000 women opted for NIPT, which was switched from in-house-developed platforms to Illumina's VeriSeq in May of this year.
Asuragen's technology will be used in the Early Check study to identify children with rare health conditions, such as fragile X syndrome, before symptoms appear.
Regenerative therapeutics company StemCyte will offer Fulgent's Beacon Expanded Carrier Screening and Newborn Genetic Analysis testing services.
The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.
The researchers said that uncovering a genetic mechanism behind the condition could aid in the development of new treatments.
The so-called enVision HPV test performed well in a comparison to Roche's Cobas HPV assay, and the Singapore researchers are considering other test applications.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
The test detects nine organisms considered to be common causes of endometritis, a condition for which no commercial molecular tests are available.
Researchers profiled the composition and gene content of microbial communities in mouth, gut, and vaginal samples collected from 10 pregnant women.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
A meta-analysis involving 16,595 women with leiomyoma and 523,330 without led to 16 associated loci related to both tumorigenesis and estrogen-related traits.
The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.
Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The firm is working on harnessing its ability to assess fetal fraction to develop new methods to predict fetal aneuploidy risks and pregnancy complications.
Clinical research has shown that the assay exhibited 100 percent sensitivity compared to culture-based testing methods, Hologic said.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.